Compare · SYM vs TMO
SYM vs TMO
Side-by-side comparison of Symbotic Inc. (SYM) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SYM and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $228.17B, about 9.5x SYM ($23.99B).
- TMO has been more active in the news (16 items in the past 4 weeks vs 6 for SYM).
- Both have 25 recent analyst ratings on file.
- Company
- Symbotic Inc.
- Thermo Fisher Scientific Inc
- Price
- -
- -
- Market cap
- $23.99B
- $228.17B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 6
- 16
- Recent ratings
- 25
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest SYM
- Director Ross Andrew D converted options into 2,568 shares, increasing direct ownership by 50% to 7,672 units (SEC Form 4)
- Chief Technology Officer Kuffner James sold $160,422 worth of shares (3,952 units at $40.59) and converted options into 9,748 shares, increasing direct ownership by 3% to 219,858 units (SEC Form 4) to cover withholding tax
- Symbotic Joins Stanford Robotics Center Industrial Affiliates Program
- Industrial Robot Installations Hit Record Highs Amid Labor Shortage Crisis
- SEC Form 3 filed by new insider Pagliuca Stephen G
- SEC Form 4 filed by Director Pagliuca Stephen G
- Amendment: SEC Form SCHEDULE 13D/A filed by Symbotic Inc.
- Director Krasnow Todd acquired 2,000 shares as part of a pre-agreed trading plan, sold $90,538 worth of shares (2,000 units at $45.27) as part of a pre-agreed trading plan and disposed of 2,000 units of Class V-1 Common Stock as part of a pre-agreed trading plan (SEC Form 4)
- Director Kane Charles sold $86,420 worth of shares (2,000 units at $43.21) as part of a pre-agreed trading plan, disposed of 2,000 units of Class V-1 Common Stock as part of a pre-agreed trading plan and acquired 2,000 shares as part of a pre-agreed trading plan, decreasing direct ownership by 85% to 89,852 units (SEC Form 4)
- Chief Financial Officer Martins Izilda P converted options into 59,134 shares and sold $1,120,490 worth of shares (27,463 units at $40.80), increasing direct ownership by 905% to 35,171 units (SEC Form 4) (for tax liability)
Latest TMO
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)
- SVP and General Counsel Shropshire Thomas B Jr. covered exercise/tax liability with 49 shares, decreasing direct ownership by 0.81% to 6,008 units (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. covered exercise/tax liability with 394 shares, decreasing direct ownership by 3% to 14,391 units (SEC Form 4)
- Sr. Vice President & CFO Meyer James covered exercise/tax liability with 270 shares, decreasing direct ownership by 5% to 5,560 units (SEC Form 4)
- Chairman & CEO Casper Marc N covered exercise/tax liability with 1,257 shares, decreasing direct ownership by 1% to 122,669 units (SEC Form 4)
- VP & Chief Accounting Officer Holmes Joseph R. covered exercise/tax liability with 50 shares, decreasing direct ownership by 2% to 2,916 units (SEC Form 4)
- President & COO Pettiti Gianluca covered exercise/tax liability with 1,035 shares, sold $2,539,233 worth of shares (4,133 units at $614.38) as part of a pre-agreed trading plan and exercised 3,733 shares at a strike of $309.63, decreasing direct ownership by 6% to 23,216 units (SEC Form 4)
- Thermo Fisher Scientific to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026
- Chairman & CEO Casper Marc N exercised 275 shares at a strike of $309.63 and sold $172,439 worth of shares (275 units at $627.05) as part of a pre-agreed trading plan (SEC Form 4)
- Sr. Vice President & CFO Meyer James covered exercise/tax liability with 31 shares, decreasing direct ownership by 0.53% to 5,830 units (SEC Form 4)